Drug Trial Radar · NCT04141423
Evaluation of Pharmacokinetics , Safety, Tolerability and Pharmacodynamics of Biocon Insulin Tregopil
Last checked: Nov 20, 2026Latest source record: Jun 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
55
Actual
Start
Oct 28, 2019
Primary completion
Apr 23, 2021
Study completion Apr 23, 2021
Sponsor
- Lead sponsor
- Biocon LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Profil Institut für Stoffwechselforschung GmbH; Juvenile Diabetes Research Foundation
- First posted
- Oct 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multi-centre, open label, multiple ascending dose trial in patients with type 1 diabetes mellitus
Conditions
- Type 1 Diabetes Mellitus (T1DM)
Interventions
TregopilDrug
Insulin Tregopil is recombinant human insulin modified by a single amphiphilic oligomer covalently linked via an amide bond to lysine at position 29 of the B-chain. This alters the physicochemical characteristics of the molecule, leading to enhanced stability and resistance to intestinal degradation following oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)Time frame: Between screening (up to Day -21) and End of study ( up to Day 6)
- Laboratory safety parametersTime frame: Between screening (up to Day -21) and End of study ( up to Day 6)
- Physical examinationTime frame: Between screening (up to Day -21) and End of study ( up to Day 6)
- Vital signs, clinicallyTime frame: Between screening (up to Day -21) and End of study ( up to Day 6)
- Hypoglycaemic eventsTime frame: Between screening (up to Day -21) and End of study ( up to Day 6)
- Hyperglycaemia eventsTime frame: Between screening (up to Day -21) and End of study ( up to Day 6)
- ElectrocardiogramsTime frame: Between screening (up to Day -21) and End of Treatment ( up to Day 6)
- Adverse events (AEs)Time frame: Day of screening to Day 20 (Diary) and During follow up Via (Telephone)
- Hypoglycaemic eventsTime frame: Day of screening to Day 20 (Diary) and During follow up Via (Telephone)
- Hyperglycaemia eventsTime frame: Day of Run-in to Day 20 (Diary) and During follow up Via (Telephone)
- Laboratory safety parametersTime frame: Day of screening and Day 20
- Physical examinationTime frame: Day of screening, Dosing day 1 and Day 20
- Vital signsTime frame: Day of screening, Day1-6 and Day 20)
- ElectrocardiogramsTime frame: Day of screening and Day 20
- Anti-insulin Tregopil antibodiesTime frame: Day -1 and Day 20
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Profil Mainz GmbH & Co. KG Malakoff-Passage,Rheinstraße 4C D-55116
Mainz, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.